Neobiomics – nutritional products for preterm infants
Neobiomics develops science-based nutritional products exclusively for preterm infants in neonatal intensive care. These are among the most vulnerable patients in medicine, and decisions made in the earliest days of life can shape outcomes for an entire lifetime.
We were founded in 2016 to translate clinical evidence into purposefully developed, high-quality products that NICU teams can rely on. Our products, ProPrems® and NeoMega36®, are developed exclusively for preterm physiology and NICU clinical routines.
Why we exist
Co-founder Dr. Stefan Johansson was, and still is, a practising consultant neonatologist and the company was built from that vantage point: a deep understanding of the everyday realities of NICUs, practical experience of what works and fails in real-world settings, and a clear awareness of how the absence of safe strategies can have serious, lifelong consequences.
From the beginning, we have focused on doing fewer things, but doing them properly. When patients are this vulnerable – precision, quality, and restraint are not limitations, they are a license to operate.
Founded by a practising neonatologist and a pharmaceutical entrepreneur.
Stefan Johansson, Co-founder and Chief Medical Officer at Neobiomics
Why we exist
We are based at Karolinska Institutet Science Park, and across the organisation, dedicated scientific expertise in neonatal nutrition keeps us close to both the evidence and the everyday realities of the NICU.
Leadership
Emma Höglund, CEO
LinkedIn
Emma Höglund brings more than 15 years of leadership across healthcare and life science, including international roles at Goldman Sachs, MSD/Merck & Co, Novartis and BCB Medical.
Stefan Johansson, CMO & Co-founder
LinkedIn
Stefan Johansson is a consultant neonatologist and associate professor, holding a PhD in Epidemiology and Biostatistics from Karolinska Institutet. He has extensive knowledge of research design through several large-scale projects and also founded the global community 99nicu.org.
Philipp Novak, Co-founder
LinkedIn
Philipp Novak brings more than 14 years of industry experience spanning veterinary medicine and pharmaceutical development.
Safety and quality
Our manufacturing partners and processes are selected to meet the highest quality standards at every stage from development to commercialization (GMP; 21 CFR part 111 and HACCP), including preterm-grade quality requirements. Production cycles are long, with continuous quality controls and stability testing integrated throughout, and we are committed to continual improvement at every stage. Both products are supported by comprehensive stability and microbiological data confirming safety and integrity throughout shelf life.
We build lasting trust with the clinical teams who rely on our products. Since launch: zero recalls and zero contamination events.
Where we operate.
200+
Contact us
Order and distribution
Partner and researcher
Frequently asked questions
When was Neobiomics founded?
Company was registered in 2016. Our first product ProPrems® was available on the market in 2019.
What is Neobiomics’ relationship with Karolinska Institutet?
Neobiomics is based at Karolinska Institutet Science Park and was part of the life science incubator DRIVE at Karolinska Institutet during 2022–2023.
Who founded the company and what are their scientific credentials?
What is the company’s mission?
Neobiomics was founded in 2016 to translate clinical evidence into safe and effective products that NICU teams can rely on.
Where is Neobiomics based?
Neobiomics is located at the heart of Karolinska Institutet Science Park, in Solna, near Stockholm in Sweden.